Reports Q2 revenue $294M, consensus $52.5M last year
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- 3 Best Stocks to Buy Now, 6/23/2023, According to Top Analysts
- Denali Therapeutics announces interim results from Phase 1/2 study of DNL310
- Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)